Details of the Drug Reposition | DrugMAP

General Information of This Drug (ID: DMZG5WL)

Drug Name	Emapalumab DMZG5WL
Synonyms	emapalumab; Emapalumab [INN]; Emapalumab [USAN:INN]; UNII-3S252O2Z4X; 3S252O2Z4X
Drug Type	Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)

1 Approved Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Primary haemophagocytic lymphohistiocytosis	DISHFGBE	4A01.23	Approved	[1]
------------------------------------------------------------------------------------

1 Phase 2/3 Indication(s)

Indication Name	Indication ID	ICD-11	Status	REF
Coronavirus Disease 2019 (COVID-19)	DISM7GNX	1D6Y	Phase 2/3	[2]
------------------------------------------------------------------------------------

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (BLA) 761107.
2	ClinicalTrials.gov (NCT04324021) Efficacy and Safety of Emapalumab and Anakinra in Reducing Hyperinflammation and Respiratory Distress in Patients With COVID-19 Infection.. U.S. National Institutes of Health.